Generic Name: apremilast
Drug Name: Otezla®
The list of clinical trials will be updated if additional studies are conducted, approved, and meet criteria for posting as explained in the Celgene Clinical Trial Data Sharing Policy.
| Unique ID | Indication / Disease | Phase | Study Name | Synopsis |
| CC-10004-PSA-001 Alternate ID: NCT00456092 EudraCT 2006-004619-23 |
Psoriatic Arthritis | Phase 2 | A phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two dose regimens of CC-10004 in subjects with active psoriatic arthritis |  |
| CC-10004-PSA-002 Alternate ID: NCT01172938 EudraCT 2010-018385-23 |
Psoriatic Arthritis | Phase 3 | A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of apremilast (CC-10004) in subjects with active psoriatic arthritis | |
| CC-10004-PSA-003 Alternate ID: NCT01212757 EudraCT 2010-018386-32 |
Psoriatic Arthritis | Phase 3 | A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of apremilast (CC-10004) in subjects with active psoriatic arthritis | |
| CC-10004-PSA-004 Alternate ID: NCT01212770 EudraCT 2010-019941-24 |
Psoriatic Arthritis | Phase 3 | A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of apremilast (CC-10004) in subjects with active psoriatic arthritis and a qualifying psoriasis lesion | |
| CC-10004-PSA-005 Alternate ID: NCT01307423 EudraCT 2010-020324-22 |
Psoriatic Arthritis | Phase 3 | A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of apremilast (CC-10004) in subjects with active psoriatic arthritis who have not been previously treated with disease-modifying antirheumatic drugs | |
| CC-10004-PSOR-001 Alternate ID: NCT00604682 |
Plaque-type Psoriasis | Phase 2 | Open-label, single-arm pilot study to evaluate the pharmacodynamics, pharmacokinetics, safety, and preliminary efficacy of CC-10004 in subjects with severe plaque type psoriasis | |
| CC-10004-PSOR-003 Alternate ID: NCT00606450 EudraCT 2006-000057-22 |
Plaque-type Psoriasis | Phase 2 | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Comparison Study of CC-10004 in Subjects With Moderate-To-Severe Plaque-Type Psoriasis | |
| CC-10004-PSOR-004 Alternate ID: NCT00521339 |
Plaque-type Psoriasis | Phase 2 | A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of CC-10004 in Subjects With Recalcitrant Plaque-Type Psoriasis | |
| CC-10004-PSOR-005 Alternate ID: NCT00773734 |
Plaque-type Psoriasis | Phase 2B | A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study) | |
| CC-10004- PSOR-008 Alternate ID: NCT01194219 EudraCT 2010-019991-55 |
Plaque-type Psoriasis | Phase 3 | A phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis | |
| CC-10004-PSOR-009 Alternate ID: NCT01232283 EudraCT 2010-019992-30 |
Plaque-type Psoriasis | Phase 3 | A phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis | |
| CC-10004-RA-002 Alternate ID: NCT01285310 2010-019926-15 |
Rheumatoid Arthritis | Phase 2 | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study, to Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate | |
| CC-10004-BCT-001 Alternate ID: NCT00866359 |
Behçet Disease | Phase 2 | A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Active-Treatment Extension to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease | |
| CC-10004-ASTH-001 | Asthma | Phase 2 | A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Comparison, Parallel-Group, Exercise Challenge Study of CC-10004 in Subjects With Mild Asthma | |